Searchable abstracts of presentations at key conferences in endocrinology

ea0092ps1-02-09 | Graves’ Disease | ETA2023

Patients` experience of being affected by graves`disease-the initial 3 month-phase

Lindo Agneta , Rivera Johansson Angelica , Fors Andreas , Filipsson Nystrom Helena

Background: Graves’ disease (GD) is the most common form of hyperthyroidism in Sweden. About 2000 patients are affected by GD annually (incidence 21/100 000) and a majority are women in working age. GD can be overwhelming for the affected patient. Health care professionals do their best to meet the patients’ needs, but can we do more? The aim of this study was to explore patients’ experiences of being affected by GD to improve healthcare.M...

ea0049ep557 | Diabetes complications | ECE2017

Meal composition affects risk markers for kidney disease differently in type 2 diabetes and healthy subjects

Olofsson Camilla , Hilding Agneta , Orsini Nicola , Andersson Inga-Lena , Torffvit Ole , Brismar Kerstin , Ekberg Neda Rajamand

Background/aims: Oxidative stress and inflammation play a role in development of diabetic kidney disease. Postprandial hyperglycemia and hyperlipidemia are speculated to be associated with increased oxidative stress and inflammation. The aim was to examine the effect of meal composition on post-prandial risk markers for kidney disease among those with type 2 diabetes (T2D) and healthy subjects (HS).Material/methods: On four occasions 21 patients with T2D...

ea0014p197 | (1) | ECE2007

Neonatal sex steroid exposure of female rats results in insulin resistance and enlarged mesenteric adipocytes

Alexanderson Camilla , Lystig Theodore , Stener-Victorin Elisabeth , Lönn Malin , Holmäng Agneta

Introduction: Neonatal events may contribute to the development of disorders such as type 2 diabetes and obesity at adult age. We have previously shown that neonatal testosterone (T) programming of female rats is followed by insulin resistance and changes in adipose tissue distribution with centralization of body fat. Therefore, the aim of this study was to examine the effects of neonatal injection of T, estradiol (E) or dihydrotestosterone (DHT) on insulin sensitivity and siz...

ea0014p196 | (1) | ECE2007

Continuous administration of dihydrotestosterone or letrozole to immature female rats results in polycystic ovary syndrome characteristics at adult age

Mannerås Louise , Lystig Theodore , Holmäng Agneta , Ottosson-Lönn Malin , Stener-Victorin Elisabet

Introduction: Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder associated with ovulatory dysfunction, hyperandrogenism, abdominal obesity and insulin resistance. Since hyperandrogenism is a PCOS key feature, the aim was to evaluate the effects of androgen receptor activation in terms of continuously administration, beginning pre-pubertal, of either the non-aromatizable androgen dihydrotestosterone (DHT) or the aromatase inhibitor letrozole (L), on...

ea0056p523 | Endocrine Disruptors | ECE2018

Plasma levels of perfluoroalkyl substances and risk of type II diabetes mellitus: a prospective nested case-control study

Donat-Vargas Carolina , Bergdahl Ingvar A. , Tornevi Andreas , Wennberg Maria , Sommar Johan , Kiviranta Hannu , Rantakokko Panu , Rolandsson Olov , AEkesson Agneta

Background: Perfluoroalkyl Substances (PFAS) have drawn much attention due to environment bioaccumulation potential and their presence worldwide in human blood. Exposure to PFAS is suspected to induce endocrine-disrupting hormonal effects and may be involved in the development of type 2 diabetes (T2D). However, epidemiological evidence is scarce and inconsistent.Objective: We aimed to investigate the association of PFAS plasma levels on the risk of devel...

ea0081p646 | Endocrine-Related Cancer | ECE2022

Methodology of the SORENTO clinical trial: assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs

Ferone Diego , Capdevilla Jaume , Ang Chan Jennifer , de Herder Wouter W , Halperin Daniel , Mailman Josh , Singh Simron , Dorkhan Mozhgan , Hellstrom Lisa , Svedberg Agneta , Tiberg Fredrik

Background: Somatostatin receptor ligands (SRLs) are first-line standard-of-care therapies for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), showing efficacy in tumour and symptom control with an established safety profile. However, disease progression may occur despite standard-dose SRL treatment, requiring more aggressive and toxic treatments. Retrospective/non-randomized data suggest higher-dose SRLs may benefit patients with GEP-NETs who do not respond to stand...

ea0089t7 | Trials In Progress | NANETS2022

Methodology of the SORENTO Clinical Trial: Assessing Efficacy and Safety of High Exposure Octreotide Subcutaneous Depot in Patients with GEP-NET

Singh, MD Simron , Capdevila, MD, PhD Jaume , Ang Chan, MD Jennifer , de Herder, MD Wouter , Ferone, MD, PhD Diego , Halperin, MD Daniel , Mailman, MBA Josh , Hellstrom, MSc Lisa , Svedberg, MSc, MBA Agneta , Tiberg, PhD Fredrik

Background: Somatostatin analogues (SSAs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET), showing efficacy in tumor/symptom control with an established safety profile. Yet, disease progression may occur despite standard-dose SSA treatment, requiring more aggressive and toxic therapies. Retrospective/non-randomized data suggest higher-dose SSAs may benefit patients with GEP-NET who do not respond to standard-dose treatment a...

ea0098t8 | Trials In Progress | NANETS2023

Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

Singh Simron , Capdevila Jaume , Ang Chan Jennifer , W de Herder Wouter , Grozinsky-Glasberg Simona , Halfdanarson Thorvardur , M Halperin Daniel , Mailman Josh , Hellstrom Lisa , Svedberg Agneta , Tiberg Fredrik , Ferone Diego

Acknowledgements: This study was funded by Camurus AB. Medical writing support was provided by Costello Medical and funded by Camurus AB.Background: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET), showing efficacy in tumor/symptom control with an established safety profile. However, disease progression usually occurs despite standard-dose SRL treatment, requiring m...